Clues From Gaucher's Disease Firm Up New Treatment Strategy For Neurodegeneration
This article was originally published in Start Up
Executive Summary
Research linking the cause of the rare genetic disorder Gaucher's disease to mechanisms at work in Parkinsonism and other neurodegenerative conditions could become the underpinning for a broad strategy to treat neurodegeneration. It's part of a growing trend looking at molecular activities in the lysosome, a cellular compartment, for drug targets.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.